ALNY(Alnylam Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $844.29M | $1.04B | $1.83B | $2.25B | $3.71B |
| 毛利润 | $729.28M | $897.24M | $1.56B | $1.94B | $3.04B |
| 营业利润 | −$708.65M | −$785.07M | −$282.18M | −$176.88M | $501.58M |
| 净利润 | −$852.82M | −$1.13B | −$440.24M | −$278.16M | $313.75M |
| 经营现金流 | −$641.69M | −$541.27M | $104.16M | −$8.31M | $524.08M |
| 自由现金流 | −$718.07M | −$613.33M | $41.95M | −$42.59M | $465.38M |
| 摊薄每股收益 | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.33 |